- Lobbying
- novo AND nordisk
Lobbying Arrangements Results for 'Novo Nordisk'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Issues related to obesity H.R. 4818/S. 2407, Treat and Reduce Obesity Act of 2023 |
Novo Nordisk Inc.
|
Team Subject Matter, LLC | |||
Details Diabetes |
Novo Nordisk
|
Mr. Thad Huguley | |||
Details |
NOVO NORDISK PHARMACEUTICALS
|
McKenna Long & Aldridge LLP | |||
Details care and treatment of diabetes |
Novo Nordisk, Inc.
|
Ms. Laura Lawlor | |||
Details FY16 Labor-Education-HHS Appropriations bills, issues related to the National Diabetes Prevention Program. H.R. 1192/S. 586, The National Diabetes Clinical Care Commission Act. |
Novo Nordisk, Inc.
|
BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ | |||
Details Issues related to Medicare and Medicaid reimbursement for pharmaceuticals. Coverage and reimbursement of obesity medications; S.595/H.R.1530, Treat and Reduce Obesity Act of 2019. General diabetes... |
Novo Nordisk Inc.
|
Thorn Run Partners | |||
Details H.R. 1577 - Treat and Reduce Obesity Act of 2021. |
Novo Nordisk, Inc.
|
HOLLAND & KNIGHT LLP | |||
Details Follow-on Biologics |
Novo Nordisk Inc.
|
COVINGTON & BURLING LLP | |||
Details Lobbying related to improved coverage of the obesity care continuum. |
Novo Nordisk Inc.
|
FGH Holdings, LLC (Formerly known as The Glover Park Group LLC) | |||
Details Extension of the National Diabetes Prevention Program (NDPP) & Medicare Part D |
Novo Nordisk
|
Johnston Group, LLC | |||
Details Treat and Reduce Obesity Act (HR 1530/S 595) |
Novo Nordisk, Inc.
|
JC HEALTH STRATEGIES, LLC | |||
Details Regulation with respect to coverage of drug categories in Medicare Part D. |
Novo Nordisk, Inc.
|
CHRISTIE 55 SOLUTIONS LLC | |||
Details Manufacturing capacity and supply chain resiliency. |
Novo Nordisk A/S
Novo Nordisk A/S is the parent of the Novo Nordisk group, a global healthcare company. |
Arnold & Porter Kaye Scholer LLP | |||
Details Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications; and other speci... |
Novo Nordisk Inc.
|
The Madison Group | |||
Details Issues related to the coverage of obesity therapeutics |
Novo Nordisk Inc.
|
PUBLIC STRATEGIES WASHINGTON, INC. | |||
Details Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Pati... |
Novo Nordisk Inc.
|
in-house lobbying | |||
Details FY 2024 appropriations: LHHS Appropriations related to Medicare Part D coverage of anti-obesity medications. Issues related to Medicare coverage of Anti Obesity Medicines. Treat and Reduce Obesity ... |
Novo Nordisk Inc.
|
NVG, LLC | |||
Details Lobbying related to the improved coverage of the obesity care continuum. |
Obesity Care Advocacy Network (OCAN)
|
FGH Holdings, LLC (Formerly known as The Glover Park Group LLC) | |||
Details Medicare and Medicaid payment and policy issues, AMP methodology issues |
NOVO NORDISK
|
SIDLEY AUSTIN LLP | |||
Details H.R.1530/S.595: Treat and Reduce Obesity Act of 2019. |
Novo Nordisk, Inc.
|
MARSHALL & POPP, LLC | |||
Details Enforcement priorities and policies regarding communications by pharmaceutical and medical device manufacturers about their medical products. |
Medical Information Working Group
|
Ropes & Gray, LLP | |||
Details Issues related to pharmacy benefit managers and the 340B Program. Issues related to pharmacy benefit managers and the 340B program. Issues related to the clinical and overall benefit of anti-obesit... |
Novo Nordisk, Inc.
|
Arnold & Porter Kaye Scholer LLP | |||
Details Health promotion and disease prevention |
Novo Nordisk, Inc.
|
M+R STRATEGIC SERVICES | |||
Details Preventative Health Savings Act (H.R. 2584/S. 1361) Drug importation, generally Issues related to the 340B Drug Pricing Program, generally H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Or... |
Novo Nordisk
|
Roberti Global (fka Roberti White, LLC) | |||
Details DOJ policy regarding off label communications. |
Medical Information Working Group
|
SIDLEY AUSTIN LLP | |||
Details H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H... |
Novo Nordisk Pharmaceuticals, Inc.
|
SLC Health Strategies, LLC | |||
Details Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy ben... |
Novo Nordisk Inc.
|
Williams and Jensen, PLLC | |||
Details Modernizing criminal sentencing concerning theft of medical products |
Coalition for Patient Safety and Medicine Integrity
|
BROWNSTEIN HYATT FARBER SCHRECK, LLP | |||
Details Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform. Health care supply chain. 340B. Treat and Reduce Obesity Act. |
Novo Nordisk Inc.
|
Todd Strategy Group | |||
Details Issues related to the prevention and treatment of diabetes, including diabetes screening; Implementation of Public Law No. 111-148, the Patient Protection and Affordable Care Act; S. Res. 242 and S... |
Novo Nordisk Inc.
|
DLA Piper LLP (US) | |||
Details IRA implementation, medication affordability and access, general diabetes prevention, obsesity Treat and Reduce Obesity Act, obesity treatment Federal budget issues |
Novo Nordisk Inc.
|
TARPLIN, DOWNS & YOUNG, LLC | |||
Details General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatme... |
Novo Nordisk Inc.
|
ALSTON & BIRD LLP | |||
Details P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agricultu... |
Novo Nordisk
|
Ryan MacKinnon Vasapoli and Berzok, LLP | |||
Details FY 2013 Budget Resolutions (diabetes-related issues). National Diabetes Prevention Program; diabetes-related issues and cost estimate legislation. S. 3295, Departments of Labor, Health and Human Se... |
NOVO NORDISK INC.
|
PODESTA GROUP, INC. |